Field Of Vision
Copyright ©2013 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastroenterol. Aug 7, 2013; 19(29): 4635-4637
Published online Aug 7, 2013. doi: 10.3748/wjg.v19.i29.4635
Stool therapy may become a preferred treatment of recurrent Clostridium difficile?
Dinesh Vyas, Heidi E L’Esperance, Arpita Vyas
Dinesh Vyas, Heidi E L’Esperance, Department of Surgery, College of Human Medicine, Michigan State University, East Lansing, MI 48912, United States
Arpita Vyas, Department of Pediatrics, College of Human Medicine, Michigan State University, East Lansing, MI 48912, United States
Author contributions: Vyas D and L’Esperance HE collected the material and wrote the manuscript; Vyas D and Vyas A discussed the topic; Vyas D supervised the publication of this commentary.
Correspondence to: Dinesh Vyas, MD, MS, FICS, Department of Surgery, College of Human Medicine, Michigan State University, 1200 East Michigan Avenue, Suite 655, East Lansing, MI 48912, United States. vyasd@msu.edu
Telephone: +1-517-2672460 Fax: +1-517-2672488
Received: February 20, 2013
Revised: May 23, 2013
Accepted: June 1, 2013
Published online: August 7, 2013
Core Tip

Core tip: Recurrent Clostridium difficile has been a challenge for patients, clinicians and hospital alike. Drug therapy for this epidemic is still not very effective. A more traditional method of fecal transplant has been discussed in this article, but it has been an uphill task to execute. We are discussing this first randomized control study, showing overarching benefits of stool transplant over traditional drug treatment. More studies needed with similar results, before making a strong recommendation in favor of it.